About Becton, Dickinson and Company
https://www.bd.comBecton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.
CEO
Thomas E. Polen Jr.
Compensation Summary
(Year 2021)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2022-04-01 | Forward | 41:40 |
| 1998-08-21 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 741
Ratings Snapshot
Rating : B
Most Recent Analyst Grades
Stifel
Buy
Morgan Stanley
Overweight
Barclays
Overweight
Wells Fargo
Equal Weight
William Blair
Market Perform
RBC Capital
Sector Perform
Grade Summary
Showing Top 6 of 8
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:32.46M
Value:$6.73B
BLACKROCK, INC.
Shares:27.75M
Value:$5.76B
BLACKROCK INC.
Shares:22.26M
Value:$4.62B
Summary
Showing Top 3 of 2,088
About Becton, Dickinson and Company
https://www.bd.comBecton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q4-2025 | $5.89B ▲ | $2.1B ▲ | $493M ▼ | 8.37% ▼ | $1.72 ▼ | $1.29B ▼ |
| Q3-2025 | $5.51B ▲ | $1.75B ▲ | $574M ▲ | 10.42% ▲ | $2 ▲ | $1.47B ▲ |
| Q2-2025 | $5.27B ▲ | $1.71B ▼ | $308M ▲ | 5.84% ▼ | $1.07 ▲ | $1.12B ▲ |
| Q1-2025 | $5.17B ▼ | $1.78B ▲ | $303M ▼ | 5.86% ▼ | $1.05 ▼ | $1.07B ▼ |
| Q4-2024 | $5.44B | $1.7B | $421M | 7.74% | $1.45 | $1.14B |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q4-2025 | $859M ▲ | $55.33B ▲ | $29.94B ▲ | $25.39B ▼ |
| Q3-2025 | $757M ▲ | $54.9B ▲ | $29.43B ▲ | $25.47B ▲ |
| Q2-2025 | $683M ▼ | $54.47B ▼ | $29.23B ▼ | $25.24B ▲ |
| Q1-2025 | $728M ▼ | $54.66B ▼ | $29.46B ▼ | $25.2B ▼ |
| Q4-2024 | $2.16B | $57.29B | $31.4B | $25.89B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q4-2025 | $493M ▼ | $1.35B ▲ | $-494M ▼ | $-809M ▲ | $53M ▲ | $1B ▼ |
| Q3-2025 | $552M ▲ | $1.22B ▲ | $-336M ▼ | $-841M ▼ | $50M ▲ | $1.04B ▲ |
| Q2-2025 | $330M ▲ | $164M ▼ | $-192M ▼ | $-39M ▲ | $-66M ▲ | $35M ▼ |
| Q1-2025 | $303M ▼ | $693M ▼ | $204M ▲ | $-1.93B ▼ | $-1.04B ▲ | $588M ▼ |
| Q4-2024 | $421M | $1.18B | $-3.94B | $124M | $-2.63B | $882M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Interventional | $1.26Bn ▲ | $1.26Bn ▲ | $1.26Bn ▲ | $1.33Bn ▲ |
 Life Sciences | $1.34Bn ▲ | $1.30Bn ▼ | $1.25Bn ▼ | $1.25Bn ▲ |
 Medical | $2.84Bn ▲ | $2.62Bn ▼ | $2.76Bn ▲ | $2.93Bn ▲ |
Revenue by Geography
| Region | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 NonUS | $2.32Bn ▲ | $2.09Bn ▼ | $2.16Bn ▲ | $2.33Bn ▲ |
 UNITED STATES | $3.12Bn ▲ | $3.08Bn ▼ | $3.11Bn ▲ | $3.18Bn ▲ |
CEO
Thomas E. Polen Jr.
Compensation Summary
(Year 2021)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2022-04-01 | Forward | 41:40 |
| 1998-08-21 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 741
Ratings Snapshot
Rating : B
Most Recent Analyst Grades
Stifel
Buy
Morgan Stanley
Overweight
Barclays
Overweight
Wells Fargo
Equal Weight
William Blair
Market Perform
RBC Capital
Sector Perform
Grade Summary
Showing Top 6 of 8
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:32.46M
Value:$6.73B
BLACKROCK, INC.
Shares:27.75M
Value:$5.76B
BLACKROCK INC.
Shares:22.26M
Value:$4.62B
Summary
Showing Top 3 of 2,088